• No results found

Cover Page The handle http://hdl.handle.net/1887/66888 holds various files of this Leiden University dissertation. Author: Mastboom, M.J.L. Title: Tenosynovial giant cell tumours Issue Date: 2018-11-13

N/A
N/A
Protected

Academic year: 2021

Share "Cover Page The handle http://hdl.handle.net/1887/66888 holds various files of this Leiden University dissertation. Author: Mastboom, M.J.L. Title: Tenosynovial giant cell tumours Issue Date: 2018-11-13"

Copied!
11
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Cover Page

The handle

http://hdl.handle.net/1887/66888

holds various files of this Leiden University

dissertation.

Author: Mastboom, M.J.L.

(2)
(3)
(4)
(5)
(6)

PROEFSCHRIFT

ter verkrijging van

de graad van Doctor aan de Universiteit van Leiden, op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,

volgens besluit van het College voor Promoties te verdedigen op dinsdag 13 november 2018

(7)

Cover design and thesis layout Lisanne de Koster ISBN 978-94-9301-479-4

Printed by Gildeprint, Enschede, the Netherlands Copyright © 2018 by Monique Mastboom

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without permission in writing from the author. The copyright of the articles has been transferred to the respective journals.

The conduction of the research included in this thesis was carried out at the Department of Orthopaedics of the Leiden University Medical Centre, Leiden, the Netherlands.

(8)

Promotores

Prof. dr. P.D.S. Dijkstra Prof. dr. A.J. Gelderblom

Co-promotor

Dr. M.A.J. van de Sande

Leden promotiecommissie

Prof. dr. J.V.M.G. Bovee

(9)

General introduction and outline of this thesis

Incidence

Higher incidence rates than previously known in Tenosynovial Giant Cell Tumours

M.J.L. Mastboom, F.G.M. Verspoor, A.J. Verschoor, D. Uittenbogaard, B. Nemeth, W.J.B. Mastboom, J.V.M.G. Bovee, P.D.S. Dijkstra, H.W.B. Schreuder, H. Gelderblom, M.A.J. van de Sande, TGCT study group.

Acta Orthop. 2017 Dec;88(6):688-694

Diagnostics

Does CSF1 over-expression or rearrangement influence biological behaviour in Tenosynovial Giant Cell Tumours of the knee?

M.J.L. Mastboom, D.M. Hoek, J.V.M.G. Bovee, M.A.J. van de Sande*, K. Szuhai* (*Shared last authorship).

Histopathology 2018 Aug. doi: 10.1111/his.13744

Disease severity

Severity classification of Tenosynovial Giant Cell Tumours on MR imaging

M.J.L. Mastboom*, F.G.M. Verspoor*, D.F. Hanff, M.G.J. Gademan, P.D.S. Dijkstra, H.W.B. Schreuder, J.L. Bloem, R.J.P. van der Wal, M.A.J. van de Sande (*Shared first authorship).

Surg Oncol. 2018 Sept;27(3):544-550

Hormones

Can increased symptoms of Tenosynovial Giant Cell Tumours during pregnancy be explained by a change in female sex hormones?

M.J.L. Mastboom, F.G.M. Verspoor, R. Planje, H.W.B. Schreuder, M.A.J. van de Sande.

(10)

114

134

162

190

Chapter 6.

Chapter 7.

Chapter 8.

Chapter 9.

Children

Tenosynovial Giant Cell Tumours in children: a similar entity compared with adults

M.J.L. Mastboom, F.G.M. Verspoor, D. Uittenbogaard, G.R. Schaap, P.C. Jutte, H.W.B. Schreuder, M.A.J. van de Sande.

Clin Orthop Relat Res. 2018 Sept;476(9):1803-1812

Localized-TGCT

Surgical treatment of localized-type Tenosynovial Giant Cell tumours of large joints

M.J.L. Mastboom, E. Staals, F.G.M. Verspoor, A.J. Rueten-Budde, S. Stacchiotti, E. Palmerini, G.R. Schaap, P.C. Jutte, W. Aston, A. Leithner, D. Dammerer, A. Takeuchi, Q. Thio, X. Niu, J.S. Wunder, TGCT study group, M.A.J. van de Sande.

Submitted

Diffuse-TGCT

Outcome of surgical treatment for patients with diffuse-type Tenosynovial Giant Cell Tumours

M.J.L. Mastboom, E. Palmerini, F.G.M. Verspoor, A.J. Rueten-Budde, S. Stacchiotti, E. Staals, G.R. Schaap, P.C. Jutte, W. Aston, H. Gelderblom, A. Leithner, D. Dammerer, A. Takeuchi, Q. Thio, X. Niu, J.S. Wunder, TGCT study group, M.A.J. van de Sande.

Submitted

Treatment

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumour

M.J.L. Mastboom*, F.G.M. Verspoor*, G. Hannink, R.G. Maki, A. Wagner, E. Bompas, J. Desai, A. Italiano, B.M. Seddon, W.T.A. van der Graaf, J.Y. Blay, M. Brahmi, L. Eberst, S. Stacchiotti, O. Mir, M.A.J. van de Sande, H. Gelderblom, P.A. Cassier (*Shared first authorship).

(11)

Quality of life

The effect of surgery in Tenosynovial Giant Cell Tumours as measured by patient reported outcomes on quality of life and joint function

M.J.L. Mastboom*, F.G.M. Verspoor*, G. Hannink, W.T.A. van der Graaf, M.A.J. van de Sande, H.W.B. Schreuder (*Shared first authorship).

Accepted in Bone Joint J

Impact on daily living

The patient perspective on the impact of Tenosynovial Giant Cell Tumours on daily living: Crowdsourcing study on physical function and quality of life

M.J.L. Mastboom, R. Planje, M.A.J. van de Sande.

Interact J Med Res. 2018 Feb 23;7(1):e4.

Limb amputation

Limb amputation after multiple treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch cases

M.J.L. Mastboom, F.G.M. Verspoor, H. Gelderblom, M.A.J. van de Sande.

Case Rep Orthop. 2017;7402570.

Summary of this thesis

Referenties

GERELATEERDE DOCUMENTEN

In part one, six MR parameters were defined by field-experts to assess disease extension on MR images: type of TGCT, articular involvement, cartilage-covered bone invasion,

To verify that diffuse-type women with increased TGCT-symptoms during pregnancy were comparable with diffuse-type women not pregnant during TGCT in the patient support

Data were derived from three sources: (1) a systematic review on TGCT in children, seeking sources published between 1990 and 2016, included 17 heterogeneous, small case-series;

In a subgroup analysis of patients with primary disease treated in a tertiary centre, the greatest risk for first local recurrence was associated with tumour size ≥5 cm

In a subgroup analysis of therapy naïve patients with diffuse- TGCT affecting the knee, surgical technique was not found to be associated with first local recurrence

Complete remission 2 (4) Partial response 15 (27) Stable disease 36 (65) Progressive disease 2 (4) Overall response rate 17 (31) Rate of disease control 53 (96) Symptomatic response

The current study, with a more homogenous, larger patient cohort and measurements at categorized time intervals, showed a similar impairment in therapy-naïve patients on

We intended to evaluate TGCT in the real world and concluded that TGCTs have a large impact on daily living, with declined health-related quality of life and limitations in